Asian Spectator

.
Business Advice

.

Guinea-Bissau’s Ministry of Finance Joins Rank of Companies Choosing N-Soft for Revenue Mobilization

HONG KONG SAR - African Media Agency - 22 April 2024 – N-Soft, a leading revenue mobilization provider for the digital age, is thrilled to announce a groundbreaking partnership with the Ministry...

Green Independent Power Producer NEFIN Supports Tech Giant NI’s 2030 Corporate Impact Strategy to Go Green

NEFIN and multinational tech firm NI to collaborate on an industrial rooftop solar panel system, for NI’s Bayan Lepas Malaysia site to offset 53,000 tons of CO2 over the lifetime of th...

In recognition of Disney’s 100-year anniversary, Riyadh Calendar Events is bringing the celebrations to Saudi Arabia in collaboration with the Saudi General Entertainment Authority (GEA).

RIYADH, SAUDI ARABIA - Media OutReach - 12 September 2023 - Running until September 20 at Boulevard Riyadh City, Disney on Ice presents '100 Years of Wonder'. The show presents world-class ...

MITSUBISHI MOTORS to Procure OEM-models from Renault for Europe

TOKYO, Mar 10, 2021 - (JCN Newswire) - As announced by the Alliance, MITSUBISHI MOTORS CORPORATION (MMC) has decided to procure two OEM-model vehicles for Europe from an Alliance member, Gr...

Microland Advances to a Premier Partner in the ServiceNow Part...

LONDON, SAN JOSE, Calif. and BENGALURU, India, Oct. 12, 2022 /PRNewswire-AsiaNet/ -- Microland announces the launch of SmartCenter 2.0 to deliver observability and hyper-automation capabilit...

Hisense Released Self-Rising Laser TV at CES 2020

LAS VEGAS, Jan. 7, 2020/PRNewswire-AsiaNet/-- Every year at CES, Hisense has brought an "evolutionary version" of laser TV. On 6th January, 2020, Hisense officially released three new Laser ...

Royal Canadian Mint issues new silver coin marking the 100th a...

CALGARY, Alberta, July 5, 2019 /PRNewswire-AsiaNet/ -- One hundred years after Calgarians chose to dedicate the greatest outdoor show on earth to Canada's returning First World War soldiers...

Sporting Goods at the 132nd Canton Fair Surge in Popularity

GUANGZHOU, China, Nov. 17, 2022 /PRNewswire-AsiaNet/ -- *Consumers From around the World Flock to the EventAt the 132nd Canton Fair, more than 800 quality makers gathered in the Sports, Trav...

TricValve(R) Transcatheter Bicaval Valves System Receives CE Mark

HONG KONG, May 20, 2021 /PRNewswire-AsiaNet/ -- OrbusNeich(R) Medical Company Ltd. and P&F Products & Features(R), under the joint partnership OrbusNeich P&F, today announced tha...

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

SYDNEY, Apr 8, 2020 - (ACN Newswire) - Asia-Pacific's largest specialist biotech CRO Novotech said the top 10 biotech sites in Australia were open for clinical trial activity with many sites modifying their practices to ensure continuity of operations.

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

View and Download the COVID-19 Australia Data Bulletin here. https://novotech-cro.com/covid-19-notice

The data is part of a new series prepared for Novotech clients detailing the current status of trials in the Asia-Pacific during the global COVID-19 crisis.

Novotech CEO Dr John Moller said the Bulletin series taps local knowledge of fundamentals in the sector and shows which countries in the region are able to support clinical research for Novotech and its clients during this time.

"While the situation is always evolving, Australia appears to be managing the crisis well. Our sites have changed how they manage trials in line with Australian Government health guidelines and most are still able to deliver the clinical trial services we need for our clients," said Dr Moller. "Study delays caused by COVID-19 can be rapidly addressed by activating new sites in Australia and Asia."

Australia has attractive start-up times, world leading investigators and research teams, and valuable rebates of up to 43.5% on clinical trial spend.

About Novotech

Novotech, established in 1996, is internationally recognized as the leading full-service contract research organization (CRO) in Asia-Pacific. Novotech provides clinical development services across all clinical trial phases and therapeutic areas and has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotech companies.

Novotech obtained the ISO 27001, the best-known standard in the ISO family, providing the requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. Visit http://novotech-cro.com.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Media ContactSusan Fitzpatrick-Napiercommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Melihat lebih dekat praktik berladang ramah lingkungan “Gilir Balik” masyarakat Ngaung Keruh (bagian 2)

Ladang Gilir Balik di antara rimbunan hutan dan kebun wanatani. Semuanya menjadi mozaik bentang alam yang turut menjaga kelestarian daerah tangkapan air Danau Sentarum.(Rifky/CIFOR), CC BY-NCBagian pe...

Ada apa dengan Manchester United? Memahami naik turunnya prestasi klub sepak bola dalam mitos ‘Sisifus’

Stadion Old Trafford di Manchester, Inggris.Nook Thitipat/ShutterstockSisifus adalah salah satu tokoh terkenal dalam mitologi Yunani kuno. Ia memiliki peran penting dalam sejarah, termasuk sebagai pen...

Sulitnya televisi lokal bermigrasi digital, bagaimana solusinya?

Dunia penyiaran kita masih menyimpan persoalan kompleks yang belum ada jalan keluarnya. Amanah Undang-Undang (UU) No. 32 Tahun 2002 tentang Penyiaran yang memiliki semangat desentralisasi kepemilikan ...



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion